Landmark Study Highlights Prognostic Value of Liquid Biopsy in Large B-Cell Lymphoma

Foresight Diagnostics Announces Publication of Landmark Study Demonstrating Prognostic Value of Ultrasensitive ctDNA-MRD Detection in Large B-Cell Lymphoma

BOULDER, Colo., Aug. 18, 2025 /PRNewswire/ -- Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection, today announced the publication of a landmark pooled analysis in the Journal of Clinical Oncology demonstrating that MRD analysis using Foresight CLARITY™…

Landmark Study Highlights Prognostic Value of Liquid Biopsy in Large B-Cell Lymphoma

A groundbreaking study reveals ctDNA testing outperforms traditional imaging in predicting outcomes for large B-cell lymphoma patients, enhancing treatment strategies.

DNA Test Outperforms PET/CT Scans When Detecting Lymphoma

ctDNA-MRD testing better predicted outcomes versus PET/CT scans for large B-cell lymphoma, leading to NCCN guideline updates for remission assessment.